<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116462</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308G301</org_study_id>
    <nct_id>NCT05116462</nct_id>
  </id_info>
  <brief_title>Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer</brief_title>
  <official_title>A Multi-Regional, Randomized, Double-blind, Phase 3 Study of the Efficacy and Safety of Sintilimab Plus Chemotherapy vs Placebo Plus Chemotherapy Before Surgery and Sintilimab vs Placebo After Surgery for Resectable Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-regional, randomized, double-blind Phase 3 study to compare the&#xD;
      efficacy and safety of sintilimab plus chemotherapy (sintilimab combination) vs placebo plus&#xD;
      chemotherapy (placebo combination) before surgery and sintilimab vs placebo after surgery in&#xD;
      treatment-naive subjects with resectable Stage IIB (primary tumor &gt; 4 cm) to IIIB (resectable&#xD;
      N2 only) non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 11, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Up to approximately 2 years following the beginning of Post-operative Assessment baseline(up to Study 5.4 years )</time_frame>
    <description>EFS is defined as the time from randomization to the first recorded time to any first documented progression, recurrence or death, which occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) Rate</measure>
    <time_frame>Up to approximately 6 weeks following completion of neoadjuvant treatment (up to Study 2 years)</time_frame>
    <description>pCR rate is defined as absence of residual invasive viable tumor in both the primary tumor (lung) and the sampled lymph nodes after neoadjuvant therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Up to approximately 2 years following the begining of Post-operative Assessment baseline(up to Study 5.4 years )</time_frame>
    <description>DFS is defined as the time from surgery to disease recurrence or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Pathological Response (mPR) Rate</measure>
    <time_frame>Up to approximately 6 weeks following completion of neoadjuvant treatment (up to Study 2 years)</time_frame>
    <description>mPR rate is defined as ≤ 10% residual invasive viable tumor in both the primary tumor (lung) and the sampled lymph nodes after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 5.4 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters: AEs</measure>
    <time_frame>Up to approximately 5.4 years</time_frame>
    <description>The relationship of study drug and the severity of all adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters:IRRs</measure>
    <time_frame>Up to approximately 5.4 years</time_frame>
    <description>The relationship of study drug and the severity of infusion-related reactions (IRRs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters: surgery delay rate</measure>
    <time_frame>Up to approximately 5.4 years</time_frame>
    <description>The relationship of study drug and the severity of surgery delay rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity-ADA</measure>
    <time_frame>Up to approximately 1.6 years</time_frame>
    <description>The positive rate of anti-drug antibody (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity-NAb</measure>
    <time_frame>Up to approximately 1.6 years</time_frame>
    <description>The positive rate of neutralizing antibody (NAb)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Treatment period: up to 3 cycles of sintilimab plus platinum-based chemotherapy prior to surgery.&#xD;
adjuvant Treatment period: Subjects will receive sintilimab therapy after surgery until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of postoperative treatment with either sintilimab or placebo is 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Neoadjuvant Treatment period: up to 3 cycles of placebo plus platinum-based chemotherapy prior to surgery.&#xD;
adjuvant Treatment period: Subjects will receive placebo therapy after surgery until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of postoperative treatment with either sintilimab or placebo is 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200 mg D1 IV Q3W</description>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 or 6 mg/ml/min D1 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>100 mg/m2 D1, 8, 15 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2 D1 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 D1 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>60 or 75 mg/m2 D1 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 or 200 mg/m2 D1 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 or 1250 mg/m2 D1, 8 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 ml D1 IV Q3W</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must sign the written informed consent form (ICF), and be able to follow the&#xD;
             visits and relevant procedures specified in the protocol.&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. Cytologically or histologically confirmed primary NSCLC (including adenocarcinoma,&#xD;
             squamous cell carcinoma).&#xD;
&#xD;
          4. Subjects with Stage IIB (primary tumor &gt; 4 cm), IIIA or IIIB (resectable N2 only)&#xD;
             disease based on the 8th edition of the TNM staging classification for lung cancer&#xD;
             issued by the International Association for the Study of Lung Cancer and the American&#xD;
             Joint Committee on Cancer Classification (AJCC8).&#xD;
&#xD;
          5. Deemed radically resectable with curative intent.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.&#xD;
&#xD;
          7. Have not received any prior systemic anti-tumor therapy or local radiotherapy for&#xD;
             NSCLC.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with confirmed or suspected brain metastases.&#xD;
&#xD;
          2. Currently participating in an interventional clinical study or treatment with another&#xD;
             study drug or study device within 4 weeks prior to randomization.&#xD;
&#xD;
          3. Received Chinese herbal medicine, Chinese traditional medicine with anti-tumor&#xD;
             indications, or drugs with immunomodulatory effects (including thymosin, interferon,&#xD;
             interleukin) within two weeks prior to randomization&#xD;
&#xD;
          4. Received a live attenuated vaccine 4 weeks prior to randomization (or planned to&#xD;
             receive a live attenuated vaccine during the study).&#xD;
&#xD;
          5. Requiring long term systemic corticosteroids&#xD;
&#xD;
          6. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody&#xD;
             positive), known active syphilis.&#xD;
&#xD;
          7. Active hepatitis B. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rong Xing</last_name>
    <phone>+86 010 87705665</phone>
    <email>Rong.Xing@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Caicun Zhou</last_name>
      <phone>021-65115006-3049</phone>
      <email>caicunzhoudr@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

